Parkman Healthcare Partners LLC Sells 30,042 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

Parkman Healthcare Partners LLC decreased its position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 22.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 105,334 shares of the company's stock after selling 30,042 shares during the period. Parkman Healthcare Partners LLC owned approximately 0.12% of NewAmsterdam Pharma worth $1,749,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in NAMS. Janus Henderson Group PLC raised its holdings in shares of NewAmsterdam Pharma by 51.1% during the third quarter. Janus Henderson Group PLC now owns 1,540,729 shares of the company's stock valued at $25,607,000 after purchasing an additional 520,772 shares during the period. Decheng Capital LLC bought a new stake in shares of NewAmsterdam Pharma during the second quarter worth about $7,684,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of NewAmsterdam Pharma by 1,231.0% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company's stock worth $3,972,000 after acquiring an additional 221,305 shares in the last quarter. Millennium Management LLC grew its position in NewAmsterdam Pharma by 23.0% in the 2nd quarter. Millennium Management LLC now owns 1,165,429 shares of the company's stock worth $22,388,000 after purchasing an additional 217,902 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C grew its position in NewAmsterdam Pharma by 30.3% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 869,250 shares of the company's stock worth $16,698,000 after purchasing an additional 202,250 shares in the last quarter. Institutional investors and hedge funds own 89.89% of the company's stock.

Insider Buying and Selling at NewAmsterdam Pharma

In related news, major shareholder Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock in a transaction on Friday, November 15th. The shares were sold at an average price of $25.02, for a total value of $213,420.60. Following the transaction, the insider now owns 11,812,033 shares in the company, valued at $295,537,065.66. This trade represents a 0.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Louise Frederika Kooij sold 45,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total transaction of $707,400.00. The disclosure for this sale can be found here. Insiders sold a total of 86,803 shares of company stock valued at $1,755,307 in the last three months. Company insiders own 19.50% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on NAMS shares. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $31.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Needham & Company LLC restated a "buy" rating and set a $36.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, November 21st. Finally, Piper Sandler restated an "overweight" rating and set a $37.00 price target on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $33.80.

NewAmsterdam Pharma Stock Down 8.6 %

NAMS traded down $1.71 on Wednesday, hitting $18.27. The company's stock had a trading volume of 1,102,382 shares, compared to its average volume of 300,899. The company's 50 day simple moving average is $19.72 and its 200-day simple moving average is $18.56. NewAmsterdam Pharma has a 12 month low of $8.90 and a 12 month high of $26.35.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.